These Tregs suppress the activity of effector T cells, such as CD8+ cytotoxic T-lymphocytes (CTLs) and CD4+ helper T cells, reducing their ability to mount effective immune responses against tumor cells [58]. This evidence concerns the gene CD8A and neoplasm.